HBIO HARVARD BIOSCIENCE INC revenue, earnings and financials
For the quarter ended June 30, 2026, HARVARD BIOSCIENCE INC reported revenue of $22.7M (up 11.1% from a year earlier), net income of −$2.91M and diluted EPS of −$0.64; over the last four quarters revenue was $87.8M and net income −$10.4M; for the fiscal year ended December 2025 revenue was $86.6M, down 8.1% on the year before.
HBIO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $86.6M, gross profit $49.9M, operating income −$48.6M, net income −$56.7M (margin -65.5%), EPS −$1.28
- Fiscal year ended Dec 2024: revenue $94.1M, gross profit $54.8M, operating income −$6.21M, net income −$12.4M (margin -13.2%), EPS −$0.28
- Fiscal year ended Dec 2023: revenue $112M, gross profit $66.1M, operating income $1.89M, net income −$3.42M (margin -3.0%), EPS −$0.08
- Fiscal year ended Dec 2022: revenue $113M, gross profit $60.8M, operating income −$6.93M, net income −$9.52M (margin -8.4%), EPS −$0.23
- Fiscal year ended Dec 2021: revenue $119M, gross profit $67.7M, operating income $2.07M, net income −$288K (margin -0.2%), EPS −$0.01
HBIO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $22.7M (up 11.1% year over year), net income −$2.91M, EPS −$0.64
- Quarter ended Mar 31, 2026: revenue $20.8M (down 4.7% year over year), net income −$3.42M, EPS −$0.77
- Quarter ended Dec 31, 2025 (from the annual report): revenue $23.7M (down 3.3% year over year), net income −$2.85M, EPS $10.69
- Quarter ended Sep 30, 2025: revenue $20.6M (down 6.3% year over year), net income −$1.23M, EPS −$0.03
- Quarter ended Jun 30, 2025: revenue $20.5M (down 11.5% year over year), net income −$2.28M, EPS −$0.52
- Quarter ended Mar 31, 2025: revenue $21.8M (down 11.2% year over year), net income −$50.3M, EPS −$11.42
- Quarter ended Dec 31, 2024 (from the annual report): revenue $24.6M (down 12.8% year over year), net income $18.0K, EPS $0.01
- Quarter ended Sep 30, 2024: revenue $22.0M (down 13.4% year over year), net income −$4.80M, EPS −$0.11
- Quarter ended Jun 30, 2024: revenue $23.1M (down 19.7% year over year), net income −$2.93M, EPS −$0.07
- Quarter ended Mar 31, 2024: revenue $24.5M (down 18.2% year over year), net income −$4.69M, EPS −$0.11
- Quarter ended Dec 31, 2023 (from the annual report): revenue $28.2M (down 1.0% year over year), net income −$1.82M, EPS −$0.04
- Quarter ended Sep 30, 2023: revenue $25.4M (down 5.8% year over year), net income −$1.24M, EPS −$0.03
- Quarter ended Jun 30, 2023: revenue $28.8M (down 1.5% year over year), net income −$980K, EPS −$0.02
- Quarter ended Mar 31, 2023: revenue $30.0M (up 4.2% year over year), net income $622K, EPS $0.01
- Quarter ended Dec 31, 2022 (from the annual report): revenue $28.4M (down 14.0% year over year), net income −$1.67M, EPS −$0.04
- Quarter ended Sep 30, 2022: revenue $26.9M (down 9.2% year over year), net income −$3.41M, EPS −$0.08
- Quarter ended Jun 30, 2022: revenue $29.2M (up 0.0% year over year), net income $2.44M, EPS $0.06
- Quarter ended Mar 31, 2022: revenue $28.8M (up 6.6% year over year), net income −$6.88M, EPS −$0.17
- Quarter ended Dec 31, 2021 (from the annual report): revenue $33.1M, net income $961K, EPS $0.02
- Quarter ended Sep 30, 2021: revenue $29.7M, net income −$170K, EPS $0.00
HBIO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $6.73M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $1.44M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $14.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $1.15M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $1.26M, share buybacks n/a
HBIO balance sheet
- Jun 30, 2026: cash $6.50M, total assets $76.3M, total liabilities $68.9M, shareholders' equity $7.42M, long-term debt $36.7M
- Mar 31, 2026: cash $7.10M, total assets $77.9M, total liabilities $67.9M, shareholders' equity $10.0M, long-term debt $36.2M
- Dec 31, 2025: cash $8.61M, total assets $80.1M, total liabilities $66.3M, shareholders' equity $13.7M, long-term debt $35.9M
- Sep 30, 2025: cash $6.82M, total assets $78.0M, total liabilities $63.9M, shareholders' equity $14.1M
- Jun 30, 2025: cash $7.44M, total assets $80.1M, total liabilities $64.4M, shareholders' equity $15.7M
- Mar 31, 2025: cash $5.55M, total assets $79.8M, total liabilities $65.0M, shareholders' equity $14.8M
- Dec 31, 2024: cash $4.11M, total assets $127M, total liabilities $63.3M, shareholders' equity $63.3M, long-term debt $0
- Sep 30, 2024: cash $4.57M, total assets $131M, total liabilities $65.9M, shareholders' equity $65.3M, long-term debt $34.3M
What is HBIO's revenue?
HARVARD BIOSCIENCE INC reported $87.8M of revenue over its last four quarters, through June 30, 2026.
Is HBIO profitable?
No. HARVARD BIOSCIENCE INC lost $10.4M over the last four quarters.
What is HBIO's EPS?
Diluted earnings per share over the last four quarters were $9.25; −$0.64 in the latest quarter.